Phio Pharmaceuticals (NASDAQ:PHIO) Shares Down 8% – Should You Sell?

by · The Cerbat Gem

Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report)’s share price was down 8% on Thursday. The stock traded as low as $0.7990 and last traded at $0.80. 115,968 shares traded hands during mid-day trading, an increase of 83% from the average session volume of 63,541 shares. The stock had previously closed at $0.8699.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Thursday, October 15th. HC Wainwright reiterated a “buy” rating on shares of Phio Pharmaceuticals in a report on Wednesday, August 26th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Phio Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $14.00.

Check Out Our Latest Stock Analysis on PHIO

Phio Pharmaceuticals Stock Down 8.0%

The stock has a market cap of $9.30 million, a PE ratio of -0.62 and a beta of 0.93. The business’s 50-day simple moving average is $0.98 and its 200-day simple moving average is $1.08.

Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.36). As a group, equities research analysts anticipate that Phio Pharmaceuticals Corp. will post -1.45 earnings per share for the current fiscal year.

Phio Pharmaceuticals Company Profile

(Get Free Report)

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company focused on developing cancer immunotherapies. The company’s programs are designed to enhance the immune system’s ability to recognize and destroy tumor cells, with an emphasis on treatments that may be administered directly to the tumor or used in combination with other therapies.

Phio’s research is based on its INTASYL self-delivering RNA interference (RNAi) technology. The platform is intended to selectively silence genes involved in immune suppression and cancer progression without requiring a separate delivery vehicle.

See Also